Carmoterol was being developed by the licensee company Chiesi in clinical trials as a once-daily therapy for chronic obstructive pulmonary disease. It is a non-catechol. Reference standards of Carmoterol API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
No Data Found
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
